Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CHRNB1 | P11230 | 1/20 | 0.52 |
| ▸ | CHRNB2 | P17787 | 1/20 | 0.52 |
| ▸ | CHRNB4 | P30926 | 1/20 | 0.52 |
| ▸ | CHRNA3 | P32297 | 1/20 | 0.52 |
| ▸ | CHRNB3 | Q05901 | 1/20 | 0.52 |
| ▸ | CHRM3 | P20309 | 9/20 | 0.49 |
| ▸ | PIM1 | P11309 | 5/20 | 0.47 |
| ▸ | MKNK1 | Q9BUB5 | 2/20 | 0.46 |
| ▸ | IKBKB | O14920 | 1/20 | 0.44 |
| ▸ | FYN | P06241 | 2/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3867523 | 0.91 | PIM1 (0.46) | CHRNB1CHRNB2CHRNB4CHRNA3CHRNB3 | |
| SCHEMBL3870457 | 0.89 | MKNK1 (0.49) | CHRNB1CHRNB2CHRNB4CHRNA3CHRNB3 | |
| SCHEMBL3870698 | 0.87 | PIM1 (0.55) | CHRM3PIM1MKNK1 | |
| SCHEMBL3865850 | 0.87 | FYN (0.49) | CHRNB1CHRNB2CHRNB4CHRNA3CHRNB3 | |
| SCHEMBL3871595 | 0.86 | PIM1 (0.49) | PIM1IKBKBFYN | |
| SCHEMBL13867547 | 0.85 | PIM1 (0.54) | CHRM3PIM1MKNK1 | |
| SCHEMBL3876139 | 0.85 | PIM1 (0.55) | CHRM3PIM1FYN | |
| SCHEMBL13866769 | 0.85 | CHRNB2 (0.47) | CHRNB1CHRNB2CHRNB4CHRNA3CHRNB3 | |
| SCHEMBL3864205 | 0.84 | IKBKB (0.49) | CHRNB1CHRNB2CHRNB4CHRNA3CHRNB3 | |
| SCHEMBL3867130 | 0.83 | CHRNB4 (0.49) | CHRNB1CHRNB2CHRNB4CHRNA3CHRNB3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20140135323-A1 | OXO-SUBSTITUTED IMIDAZO[1,2B]PYRIDAZINES, THEIR PREPARATION AND USE AS PHARMACEUTICALS | BAYER INTELLECTUAL PROPERTY GMBH (DE) | 2014-05-15 | — | — | US | claimed |
| US-20090093475-A1 | Oxo-substituted imidazo[1,2b]pyridazines, their preparation and use as pharmaceuticals | BAYER INTELLECTUAL PROPERTY GMBH (DE) | 2009-04-09 | — | — | US | claimed |
| EP-2044071-A1 | OOXO-SUBSTITUTED IMIDAZO[1,2b]PYRIDAZINES, PRODUCTION AND USE THEREOF AS DRUGS | Bayer Schering Pharma Aktiengesellschaft (DE) | 2009-04-08 | — | — | EP | claimed |
| WO-2007147646-A1 | OXO-SUBSTITUTED IMIDAZO[1,2b]PYRIDAZINES, PRODUCTION AND USE THEREOF AS DRUGS | BAYER SCHERING PHARMA AKTIENGESELLSCHAFT (DE) | 2007-12-27 | — | — | WO | claimed |
| US-20140135323-A1 | OXO-SUBSTITUTED IMIDAZO[1,2B]PYRIDAZINES, THEIR PREPARATION AND USE AS PHARMACEUTICALS | BAYER INTELLECTUAL PROPERTY GMBH (DE) | 2014-05-15 | — | — | US | disclosed |
| US-20140135323-A1 | OXO-SUBSTITUTED IMIDAZO[1,2B]PYRIDAZINES, THEIR PREPARATION AND USE AS PHARMACEUTICALS | BAYER INTELLECTUAL PROPERTY GMBH (DE) | 2014-05-15 | — | — | US | disclosed |
| US-8653076-B2 | Oxo-substituted imidazo[1,2B]pyridazines, their preparation and use as pharmaceuticals | BAYER INTELLECTUAL PROPERTY GMBH (DE) | 2014-02-18 | — | — | US | disclosed |
| US-8653076-B2 | Oxo-substituted imidazo[1,2B]pyridazines, their preparation and use as pharmaceuticals | BAYER INTELLECTUAL PROPERTY GMBH (DE) | 2014-02-18 | — | — | US | disclosed |
| US-20090093475-A1 | Oxo-substituted imidazo[1,2b]pyridazines, their preparation and use as pharmaceuticals | BAYER INTELLECTUAL PROPERTY GMBH (DE) | 2009-04-09 | — | — | US | disclosed |
| US-20090093475-A1 | Oxo-substituted imidazo[1,2b]pyridazines, their preparation and use as pharmaceuticals | BAYER INTELLECTUAL PROPERTY GMBH (DE) | 2009-04-09 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090093475-A1 | Oxo-substituted imidazo[1,2b]pyridazines, their preparation and use as pharmaceuticals | CDK2, CDK1, MAP4K2 | CHRNB1 1419/4885CHRNB2 2195/4885CHRNB4 2792/4885 |
| US-20140135323-A1 | OXO-SUBSTITUTED IMIDAZO[1,2B]PYRIDAZINES, THEIR PREPARATION AND USE AS PHARMACEUTICALS | CDK2, CDK1, MAP4K2 | CHRNB1 1419/4885CHRNB2 2195/4885CHRNB4 2792/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.